Currently holds positions in BridgeBio Pharma Inc, Genentech Inc and Alector Inc
Position | Company | Period |
---|---|---|
Chairman of Research and Development, Director | BridgeBio Pharma Inc | Jan. 1, 2019 - |
Executive Vice President - Research, Chief Scientific Officer | Genentech Inc | Jan. 1, 2008 - |
Independent Director | Alector Inc | Oct. 1, 2018 - |
Independent Director | Xenon Pharmaceuticals Inc | March 16, 2015 - Jan. 14, 2020 |
Director | BridgeBio Pharma Inc | Jan. 1, 2018 - Jan. 1, 2019 |
Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | Roche Holding AG | Jan. 1, 2009 - Dec. 31, 2014 |
Search
Notification date | Transaction date | B/S Transaction type |
Nb. shares Price Value |
Number of shares | Price | Total value | Details | |
---|---|---|---|---|---|---|---|---|
2022-11-14 | 2022-11-11 |
VG Acquisition Corp
(VGAC)
|
S Sale |
18,421
-20.3%
3.2459,684 USD |
18,421 -20.3% | 3.24 | 59,684 USD | |
2021-05-24 | 2021-05-24 |
Oric Pharmaceuticals Inc
(ORIC)
|
PS Planned sale |
100
-0.3%
25.002,500 USD |
100 -0.3% | 25.00 | 2,500 USD | |
2021-05-24 | 2021-05-21 |
Oric Pharmaceuticals Inc
(ORIC)
|
PS Planned sale |
1,231
-3.0%
25.1931,008 USD |
1,231 -3.0% | 25.19 | 31,008 USD | |
2021-05-24 | 2021-05-20 |
Oric Pharmaceuticals Inc
(ORIC)
|
PS Planned sale |
659
-1.6%
25.0816,528 USD |
659 -1.6% | 25.08 | 16,528 USD | |
2021-05-18 | 2021-05-18 |
Oric Pharmaceuticals Inc
(ORIC)
|
PS Planned sale |
2,800
-6.4%
25.3470,958 USD |
2,800 -6.4% | 25.34 | 70,958 USD | |
2021-05-18 | 2021-05-17 |
Oric Pharmaceuticals Inc
(ORIC)
|
PS Planned sale |
500
-1.1%
25.0612,530 USD |
500 -1.1% | 25.06 | 12,530 USD | |
2021-05-18 | 2021-05-14 |
Oric Pharmaceuticals Inc
(ORIC)
|
PS Planned sale |
4,615
-9.4%
25.38117,117 USD |
4,615 -9.4% | 25.38 | 117,117 USD | |
2021-04-05 | 2021-04-01 |
Oric Pharmaceuticals Inc
(ORIC)
|
PS Planned sale |
200
-0.4%
25.005,000 USD |
200 -0.4% | 25.00 | 5,000 USD | |
2020-12-23 | 2020-12-21 |
BridgeBio Pharma Inc
(BBIO)
|
S Sale |
45,473
-49.8%
65.482,977,699 USD |
45,473 -49.8% | 65.48 | 2,977,699 USD | |
2020-12-23 | 2020-12-21 |
BridgeBio Pharma Inc
(BBIO)
|
S Sale |
14,928
-14.0%
64.81967,437 USD |
14,928 -14.0% | 64.81 | 967,437 USD | |
2020-12-21 | 2020-12-18 |
BridgeBio Pharma Inc
(BBIO)
|
S Sale |
2,895
-2.7%
65.78190,432 USD |
2,895 -2.7% | 65.78 | 190,432 USD | |
2020-12-21 | 2020-12-18 |
BridgeBio Pharma Inc
(BBIO)
|
S Sale |
27,105
-19.9%
64.991,761,589 USD |
27,105 -19.9% | 64.99 | 1,761,589 USD | |
2020-12-17 | 2020-12-15 |
BridgeBio Pharma Inc
(BBIO)
|
S Sale |
19,352
-12.4%
60.731,175,303 USD |
19,352 -12.4% | 60.73 | 1,175,303 USD | |
2020-12-17 | 2020-12-15 |
BridgeBio Pharma Inc
(BBIO)
|
S Sale |
12,091
-7.2%
59.81723,114 USD |
12,091 -7.2% | 59.81 | 723,114 USD | |
2020-09-18 | 2020-09-16 |
BridgeBio Pharma Inc
(BBIO)
|
PS Planned sale |
25,000
-15.3%
37.50937,500 USD |
25,000 -15.3% | 37.50 | 937,500 USD | |
2020-02-06 | 2020-02-04 |
Alector Inc
(ALEC)
|
PS Planned sale |
10,000
-50.0%
29.67296,700 USD |
10,000 -50.0% | 29.67 | 296,700 USD | |
2004-05-17 | 2004-05-13 |
Genentech Inc
(DNA)
|
S Sale |
100
-100.0%
61.616,161 USD |
100 -100.0% | 61.61 | 6,161 USD | |
2004-05-17 | 2004-05-13 |
Genentech Inc
(DNA)
|
S Sale |
500
-100.0%
61.6030,800 USD |
500 -100.0% | 61.60 | 30,800 USD | |
2004-05-17 | 2004-05-13 |
Genentech Inc
(DNA)
|
S Sale |
800
-100.0%
61.5949,272 USD |
800 -100.0% | 61.59 | 49,272 USD | |
2004-05-17 | 2004-05-13 |
Genentech Inc
(DNA)
|
S Sale |
5,893
-100.0%
61.58362,891 USD |
5,893 -100.0% | 61.58 | 362,891 USD | |
2004-05-07 | 2004-05-06 |
Genentech Inc
(DNA)
|
S Sale |
1,354
-100.0%
124.00167,896 USD |
1,354 -100.0% | 124.00 | 167,896 USD | |
2004-05-07 | 2004-05-06 |
Genentech Inc
(DNA)
|
S Sale |
2,604
-100.0%
124.00322,896 USD |
2,604 -100.0% | 124.00 | 322,896 USD |